1. Redox imbalance in Crohn's disease patients is modulated by Azathioprine
- Author
-
Zahra Salehi, Mohammad Hossein Nicknam, Mohammad Reza Pourmand, Mohammad Javad Tavassolifar, Mostafa Changaei, Moslem Javidan, and Fatemeh Ghasemi
- Subjects
peripheral blood mononuclear cell ,crohn's disease ,QH301-705.5 ,Physiology ,Clinical Biochemistry ,Inflammation ,Azathioprine ,Disease ,medicine.disease_cause ,Biochemistry ,Inflammatory bowel disease ,Peripheral blood mononuclear cell ,Antioxidants ,Crohn Disease ,inflammatory bowel disease ,Pathology ,medicine ,Humans ,RB1-214 ,Biology (General) ,reactive oxygen species ,chemistry.chemical_classification ,Reactive oxygen species ,Crohn's disease ,business.industry ,Biochemistry (medical) ,food and beverages ,Cell Biology ,medicine.disease ,Oxidative Stress ,chemistry ,redox ,Immunology ,medicine.symptom ,business ,Oxidation-Reduction ,Oxidative stress ,Research Article ,medicine.drug - Abstract
Background Crohn's disease (CD) is a chronic inflammatory disease without a specific cause. Inflammation in these patients can disturb the oxidants/antioxidants balance and results in oxidative stress that plays a destructive role. This study aimed to evaluate the gene expression of sod1, sod2, cat, nrf2 and gp91phox in CD patients before and after Azathioprine (Aza) consumption. Method Peripheral bloodmononuclear cells (PBMCs) were separated from CD patients (n= 15, mean age = 33.6 ± 1.8) before and after treatment with Aza and healthy controls (n= 15, mean age = 31.5 ± 1.2). The expression levels of sod1, sod2, cat, nrf2 and gp91phox were measured in byusing real-time qRT-PCR technique. Result The expression levels of gp91phox (P-value
- Published
- 2021
- Full Text
- View/download PDF